phosphatidylinositol 4-kinase type 2 betaGenealiases: PI4KIIB · PIK42B
Q-omics provides the consensus-scored PI4K2B profile across patient tissues and cancer cell-line models. PI4K2B expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, PI4K2B is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, PI4K2B RNA expression shows 19,642 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, THCA, and UVM as cancer lineages where PI4K2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PI4K2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PI4K2B survival associations across molecular data types. PI4K2B RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PI4K2B RNA expression–survival associations across cancer types. High PI4K2B expression shows unfavorable associations in UVM, LGG and HNSC, but favorable associations in SKCM, UCS and KIRC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for PI4K2B RNA expression.
This table summarizes PI4K2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 7. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PI4K2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PI4K2B shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, STAD, BRCA and LUAD. The THCA box plot shows higher PI4K2B RNA expression in normal versus tumor tissue (log2 FC = −0.980, t-test p < 0.001).
This table shows molecular features associated with PI4K2B in patient tissues and cancer cell lines. In patient samples, PI4K2B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PI4K2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
